[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese Academy of Medical Sciences, Fuwai Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":644},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,40,66,99,123,157,185,222,244,265,283,301,321,351,370,400,423,449,469,496,523,548,575,598,624],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100637767","effects-of-remimazolam-on-neurocognitive-function-in-patients-undergoing-cardiovascular-surgery-100637767",false,"NCT07598019","Effects of Remimazolam on Neurocognitive Function in Patients Undergoing Cardiovascular Surgery","Effects of Remimazolam on Neurocognitive Function in Patients Undergoing Cardiovascular Surgery (the EFFICACY Study)","Inclusion Criteria:\n\n1. Male or female adult patients aged 60 years or older\n2. Receiving elective cardiovascular surgery with cardiopulmonary bypass\n3. Written Informed consent provided\n\nExclusion Criteria:\n\n1. Deep hypothermia circulatory arrest\n2. Breastfeeding or pregnancy\n3. Mental or legal disability\n4. Terminal illness with a life expectancy of less than 3 months\n5. Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments","ALL","60 Years",{"count":20,"type":21},210,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to explore the effect of remimazolam-based total intravenous anesthesia on postoperative neurocognitive function in patients who undergo cardiovascular surgery.\n\nThe main question this study tries to answer is: Does remimazolam influence the incidence of postoperative delirium in cardiovascular surgery? Participants already apply remimazolam-based total intravenous anesthesia as part of their regular medical treatment for general anesthesia to perform cardiac surgery will answer questionnaires about cognitive function after surgery.",[25,26],"Neurocognitive Disorder","Cardiac Surgery","NOT_YET_RECRUITING","2026-05-13",{"date":30,"type":31},"2026-05-20","ACTUAL",{"date":33,"type":21},"2026-06-15",{"date":35,"type":21},"2027-12-30",{"name":37,"class":38},"Chinese Academy of Medical Sciences, Fuwai Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100627558","a-prospective-multicenter-observational-study-evaluating-safety-and-effectiveness-of-sapien-3-transcatheter-aortic-valve-replacement-for-type-0-bicuspid-aortic-valve-stenosis-patients-in-china-100627558","NCT07450196","A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Replacement for Type-0 Bicuspid Aortic Valve Stenosis Patients in China","ASCENT","Inclusion Criteria:\n\n* Age ≥50 years, and after thorough physician-patient discussion and shared decision-making, willing to undergo or accept TAVR.\n* Severe AS, defined as follows:\n\n  a) For symptomatic patients: i) Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2\u002Fm2), OR mean gradient ≥40 mm Hg, OR Maximal aortic valve velocity ≥4.0 m\u002Fsec by transthoracic echocardiography at rest b) For asymptomatic patients: i) Very severe AS with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2\u002Fm2), AND maximal aortic velocity ≥5.0 m\u002Fsec, or mean gradient ≥60 mm Hg by transthoracic echocardiography at rest, OR ii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2\u002Fm2), AND a mean gradient ≥40 mm Hg or maximal aortic valve velocity ≥4.0 m\u002Fsec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR iii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2\u002Fm2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m\u002Fsec by transthoracic echocardiography at rest, AND a left ventricular ejection fraction \\\u003C50%.\n* Type-0 bicuspid aortic valve anatomy confirmed by multi-detector computed tomography (MDCT).\n* The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.\n* Adequate iliofemoral access and acceptable level of vessel calcification and tortuosity for safe device implant.\n* The study patient has provided written informed consent.\n\nExclusion Criteria:\n\n* Challenging calcification based on physician's experience and discretion\n* Aortic valve is a congenital unicuspid valve, congenital Type-1 or Type-2 bicuspid valve, tricuspid or quadricuspid valve\n* Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR\n* Need for open heart surgery (including severe aortic regurgitation, mitral regurgitation or stenosis, or tricuspid regurgitation, congenital heart disease, AF, complex coronary artery disease)\n* Pre-existing mechanical or bioprosthetic valve in any position\n* Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of the screening visit\n* Emergency interventional\u002Fsurgical procedures within 30 days of the valve implant procedure\n* Hypertrophic cardiomyopathy with obstruction\n* Ventricular dysfunction with LVEF \\\u003C 30%\n* Cardiac imaging (echo, CT, and\u002For MRI) evidence of ventricular mass, thrombus or vegetation\n* Renal replacement therapy at the time of screening\n* Estimated life expectancy \\\u003C 12 months\n* Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. Observational studies are not considered exclusionary.","50 Years",{"count":49,"type":21},170,"In China, bicuspid aortic valve (BAV) represents a significantly high proportion of the transcatheter aortic valve replacement (TAVR) population. The application of TAVR in patients with BAV is challenging due to complex anatomy. To date, no prospective study has evaluated the Sapien 3 TAVR in patients with Type-0 BAV.",[52,53],"Aortic Stenosis","AORTIC VALVE DISEASES",[55,56,57],"Balloon-expandable transcatheter heart valve","TAVR","aortic stenosis","2026-05-03",{"date":60,"type":31},"2026-05-07",{"date":62,"type":21},"2026-04-15",{"date":64,"type":21},"2029-08-31",{"name":37,"class":38},{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100636467","covered-vs-bare-metal-stents-for-atherosclerotic-renal-artery-stenosis-100636467","NCT07566065","Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis","Endovascular Treatment of Atherosclerotic Renal Artery Stenosis: A Prospective Randomized Controlled Study Comparing Covered Stents and Bare Metal Stents","COMBAT","Inclusion Criteria:\n\n* 1\\) Renal artery diameter stenosis ≥60%; 2) Office systolic blood pressure ≥ 160 mmHg and\u002For office diastolic blood pressure ≥ 100 mmHg on at least two separate days without antihypertensive medication, or office systolic blood pressure ≥ 140 mmHg and\u002For office diastolic blood pressure ≥ 90 mmHg while on three antihypertensive drugs at conventional doses; 3) Serum creatinine \\\u003C 264 μmol\u002FL (3.0 mg\u002FdL); 4) Affected kidney length ≥ 7.0 cm, with residual glomerular filtration rate (GFR) ≥ 10 mL\u002Fmin;\n\nExclusion Criteria:\n\n* 1\\) Unstable clinical condition rendering the patient intolerant to revascularisation therapy; 2) Urinary protein ≥2+; 3) Contrast medium allergy; 4) Renal artery anatomy unsuitable for revascularisation therapy; 5) Reference vessel diameter \\\u003C3.5mm or \\>8mm. 6)Patients with non-atherosclerotic renal artery stenosis (such as fibromuscular dysplasia or Takayasu arteritis); 7)Reference vessel diameter \\\u003C 3.5 mm or \\> 8 mm","40 Years","80 Years",{"count":77,"type":21},150,"INTERVENTIONAL",[80],"NA","Atherosclerotic renal artery stenosis is the most common cause of secondary hypertension , increasing the risk of cardiovascular and kidney-related complications. Some small-scale studies have suggested that covered stents are effective and safe, but high-quality evidence from large-scale studies in atherosclerotic renal artery stenosis remains limited.\n\nThis study aims to evaluate whether covered stents are more effective than bare metal stents in patients with atherosclerotic renal artery stenosis. Eligible participants will be randomly assigned to receive either a covered stent or a bare metal stent. Patients will be followed for 12 months to assess Changes in eGFR, 24-hour systolic blood pressure, and 24-hour diastolic blood pressure from baseline to 12 months were compared among the groups.\n\nThe results of this study may help improve treatment strategies and guide the selection of stent type for patients with this condition.",[83,84,85],"Atherosclerotic Renal Artery Stenosis","Hypertension","Renal Artery Stenosis",[87,88,89],"covered stents","bare metal stents","atherosclerotic renal artery stenosis","2026-04-27",{"date":92,"type":31},"2026-05-04",{"date":94,"type":21},"2026-04-30",{"date":96,"type":21},"2028-04-30",{"name":37,"class":38},15,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":107,"targetDuration":4,"studyType":78,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":116,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100632255","ffr-guided-revascularization-in-atherosclerotic-renal-artery-stenosis-100632255","NCT07511309","FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis","Fractional Flow Reserve-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial","FARS","Inclusion Criteria:\n\n1. Renal artery diameter stenosis ≥60%;\n2. Office systolic blood pressure ≥ 160 mmHg and\u002For office diastolic blood pressure ≥ 100 mmHg on at least two separate days without antihypertensive medication, or office systolic blood pressure ≥ 140 mmHg and\u002For office diastolic blood pressure ≥ 90 mmHg while on three antihypertensive drugs at conventional doses;\n3. Serum creatinine \\\u003C 264 μmol\u002FL (3.0 mg\u002FdL);\n4. Affected kidney length ≥ 7.0 cm, with residual glomerular filtration rate (GFR) ≥ 10 mL\u002Fmin;\n\nExclusion Criteria:\n\n1. Unstable clinical condition rendering the patient intolerant to revascularisation therapy;\n2. Urinary protein ≥2+;\n3. Contrast medium allergy;\n4. Renal artery anatomy unsuitable for revascularisation therapy;\n5. Reference vessel diameter \\\u003C3.5mm or \\>8mm.\n6. Patients with non-atherosclerotic renal artery stenosis (such as fibromuscular dysplasia or Takayasu arteritis);\n7. Reference vessel diameter \\\u003C 3.5 mm or \\> 8 mm.",{"count":108,"type":21},300,[80],"For patients with atherosclerotic renal artery stenosis, the results of randomized controlled trials published in recent years have failed to demonstrate that renal artery stenting is superior to optimal medical therapy. However, these studies still have limitations.\n\nFractional flow reserve (FFR) has been extensively studied in coronary artery disease, and it has been established that FFR-guided revascularization is superior to both angiography-guided percutaneous coronary intervention and medical therapy alone. Whether FFR can guide interventional treatment in patients with renal artery stenosis and hypertension is currently a hot topic in the field of renal artery stenosis research.\n\nEligible patients meeting the inclusion criteria were enrolled. Pharmacologically induced FFR values were measured as the baseline. Patients with FFR ≥ 0.8 were randomly assigned to either the medical therapy group or the stenting group, while patients with FFR \\\u003C 0.8 underwent stent implantation. Changes in eGFR, 24-hour systolic blood pressure, and 24-hour diastolic blood pressure from baseline to 12 months were compared among the groups.",[83,112,113,114],"Fractional Flow Reserve","Optimal Medical Therapy","Stent Implantation",[83,112,113],{"date":94,"type":31},{"date":118,"type":21},"2026-03-31",{"date":120,"type":21},"2028-03-31",{"name":37,"class":38},20,{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":78,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100628491","phase-4-proteomic-and-inflammatory-omics-changes-with-colchicine-therapy-in-coronary-heart-disease-100628491","NCT07462325","Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease","Proteomic Changes Before and After Colchicine Treatment in hsCRP-Elevated Coronary Heart Disease Patients: A Randomized Controlled Open-Label Study","PIC-CHD","Inclusion Criteria:\n\n* Diagnosis \\& Treatment: Have symptoms or objective evidence of myocardial ischemia and have undergone successful Percutaneous Coronary Intervention (PCI).\n\nInflammation Status: Have a plasma high-sensitivity C-reactive protein (hs-CRP) level ≥ 2 mg\u002FL at the time of screening.\n\nBackground Therapy: Be on guideline-directed standard medical therapy for coronary heart disease, tailored to their individual clinical condition.\n\nInformed Consent: The participant or their legally authorized representative must be capable of understanding the study and must provide written informed consent.\n\nExclusion Criteria:\n\n* Recent Cardiac Event: Acute Myocardial Infarction within the past 1 month. Drug Intolerance: Known allergy or intolerance to colchicine.\n\nHematologic Abnormalities:\n\nPlatelet count \\\u003C 110 × 10⁹\u002FL White blood cell count \\\u003C 4.0 × 10⁹\u002FL Hemoglobin level \\\u003C 115 g\u002FL\n\nRenal Impairment:\n\nEstimated Glomerular Filtration Rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (calculated using the MDRD formula), OR Serum creatinine level \\> 2 times the upper limit of normal (ULN).\n\nHepatic Impairment:\n\nSevere liver cirrhosis, biliary cirrhosis, or cholestasis, OR Liver enzyme (transaminase) levels \\> 3 times the ULN. Bone Marrow Disorder: Known history of bone marrow hypoplasia.\n\nSevere Cardiac Conditions:\n\nNew York Heart Association (NYHA) Class III-IV heart failure, OR Left Ventricular Ejection Fraction (LVEF) \\\u003C 35%, OR Moderate or severe valvular heart disease requiring intervention. Recent Cerebrovascular Event\u002FInstability: Stroke within the past 3 months, or current cardiogenic shock or hemodynamic instability.\n\nActive Malignancy: Concurrent active tumor or cancer. Chronic Pulmonary Disease: Chronic Obstructive Pulmonary Disease (COPD) or other chronic lung diseases.\n\nInflammatory Bowel Disease (IBD) or Chronic Diarrhea: e.g., Crohn's disease, ulcerative colitis.\n\nUncontrolled Comorbidities: Any other uncontrolled disease or condition that, in the investigator's judgment, would place the participant at undue risk by participating in the study.\n\nActive Systemic Inflammation\u002FInfection: Presence of systemic inflammation or acute infection at the time of enrollment.\n\nConcurrent Steroid Use: Current use or planned initiation of systemic corticosteroid therapy during the study period (excluding topical or inhaled steroids).\n\nPregnancy\u002FBreastfeeding: Women who are pregnant, planning to become pregnant, or breastfeeding.\n\nConcurrent Trial Participation: Participation in another interventional clinical trial within the past 3 months that may interfere with the outcomes of this study.","18 Years","85 Years",{"count":134,"type":21},176,[136],"PHASE4","The goal of this exploratory clinical trial is to investigate the proteomic changes induced by low-dose colchicine anti-inflammatory therapy in coronary heart disease (CHD) patients, with the aim of identifying novel biomarkers and therapeutic targets.\n\nThe main questions it aims to answer are:\n\n* Whether short-term colchicine treatment induces significant changes in the plasma proteomic profile of post-PCI CHD patients with residual inflammation.\n* Which specific proteins or pathways are dynamically modulated by colchicine, indicating potential mechanisms of action and drug targets.\n* How the proteomic expression profiles differ between patients treated with colchicine and matched controls after one month.\n\nParticipants, recruited based on a prior RCT framework, will be post-PCI CHD patients with elevated inflammation (hs-CRP ≥ 2 mg\u002FL). A total of 176 participants will be enrolled: 88 in the trial group (colchicine 0.5 mg\u002Fday) and 88 in the matched control group (no intervention). All participants will complete a one-month follow-up. Peripheral blood samples will be collected at baseline and at the one-month visit for high-throughput proteomic analysis using Olink technology.",[139],"Coronary Heart Disease (CHD)",[141,142,143,144,145,146,147,148],"Colchicine","Proteomics","Biomarkers","Olink","Anti-Inflammatory Therapy","Randomized Controlled Trial (RCT)","High-Throughput Screening","Precision Medicine","2026-03-17",{"date":151,"type":31},"2026-03-19",{"date":153,"type":21},"2026-03-01",{"date":155,"type":21},"2027-03-31",{"name":37,"class":38},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":164,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":78,"phases":167,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":39},"100597134","phase-4-a-novel-echocardiography-guided-strategy-for-percutateous-closure-of-atrial-septal-defect-assisted-by-pannawire-100597134","NCT07054541","A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire","PANNA-ASD","RCT Eligibility Criteria\n\nInclusion Criteria:\n\n* Age ≥ 2 years\n* Diagnosed with secundum-type atrial septal defect (ASD) with a diameter ≥ 6 mm and ≤ 36 mm, accompanied by right heart volume overload\n* The distance from the defect margin to the coronary sinus, inferior vena cava, superior vena cava, and pulmonary veins is ≥ 5 mm; the distance to the atrioventricular valve is ≥ 7 mm\n\nExclusion Criteria:\n\n* Pregnant women\n* Contrast agent allergy\n* Renal insufficiency\n* Associated cardiac malformations requiring surgical intervention\n* Right-to-left shunt ASD\n* Ostium primum ASD and sinus venosus ASD\n* Any severe infection within one month before the procedure\n* Intracardiac thrombus\n\nCohort Eligibility Criteria：\n\nInclusion Criteria:\n\n* Age ≥ 2 years\n* Diagnosed with secundum-type atrial septal defect (ASD) with a diameter ≥ 6 mm and ≤ 36 mm, accompanied by right heart volume overload\n* The distance from the defect margin to the coronary sinus, inferior vena cava, superior vena cava, and pulmonary veins is ≥ 5 mm; the distance to the atrioventricular valve is ≥ 7 mm\n* Contraindications to radiation exposure or refusal to undergo fluoroscopy-guided procedures\n\nExclusion Criteria:\n\n* Associated cardiac malformations requiring surgical intervention\n* Right-to-left shunt ASD\n* Ostium primum ASD and sinus venosus ASD\n* Any severe infection within one month before the procedure\n* Intracardiac thrombus","2 Years",{"count":166,"type":21},666,[136],"Atrial septal defect (ASD) is a common congenital heart disease, and percutaneous interventional therapy is the main and effective treatment. Traditional percutaneous closure procedures are performed under fluoroscopic guidance and require contrast agents. A retrospective analysis of over 20,000 adult patients with congenital heart disease revealed that even low-dose radiation exposure was significantly associated with an increased long-term risk of malignancy. Moreover, the use of contrast agents carries the risk of allergic reactions and kidney injury. Radiation and contrast agents not only pose iatrogenic harm to patients but also limit the use of interventional techniques in special populations, such as pregnant women, patients with contrast agent allergies, or those with renal insufficiency.\n\nTo achieve radiation-free and contrast-free interventional closure procedures, researchers have developed ultrasound-guided percutaneous interventional techniques, yielding satisfactory treatment outcomes. In some cases, these techniques have even enabled cardiovascular procedures to be performed on an outpatient basis, significantly reducing hospitalization time and costs.\n\nThis project proposes a large-sample, multicenter, prospective randomized controlled study to determine whether ultrasound-guided percutaneous intervention for ASD with the assistance of specialized instruments is non-inferior to traditional fluoroscopy-guided procedures, while also offering shorter hospital stays and lower medical expenses.In addition, patients with radiation contraindications or who refuse radiation therapy, and who are willing to undergo ultrasound-guided percutaneous atrial septal defect (ASD) closure with the assistance of dedicated devices, will be enrolled in a separate observational cohort (observational cohort study).",[170],"Atrial Septal Defect (ASD)",[172,173,174,175,176,177,178],"Ultrasound-guided","Percutaneous Intervention","Atrial Septal Defect","Pannawire","PAN Procedure","ASD closure","non fluoroscopic","2026-03-14",{"date":149,"type":31},{"date":179,"type":21},{"date":183,"type":21},"2027-10-31",{"name":37,"class":38},{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":78,"phases":195,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":39},"100593492","phase-4-strategies-for-antithrombotic-treatment-following-transcatheter-edge-to-edge-repair-in-patients-without-an-indication-for-oral-anticoagulant-100593492","NCT07007143","STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant","STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-edge Repair in Patients Without an Indication for Oral Anticoagulant: a Multicenter Randomized Controlled Trial","STAR-TEER Ⅱ","Inclusion Criteria:\n\n* Successful TEER procedure, defined as technical success per MVARC criteria.\n* Ability and willingness to comply with the trial protocol.\n* Provision of written informed consent.\n* Women of childbearing potential must use effective contraception from the time of consent until the final dose of antithrombotic therapy.\n* Antithrombotic strategy approved by the investigator.\n\nExclusion Criteria:\n\n* Severe renal impairment (creatinine clearance \\\u003C 15 mL\u002Fmin or requiring dialysis).\n* Ongoing postoperative bleeding (defined as overt bleeding with a ≥3.0 g\u002FdL drop in hemoglobin or requiring ≥3 units of blood transfusion), or vascular complications following the index TEER procedure.\n* Platelet count \\\u003C 50 × 10\\^9 \u002FL.\n* Need for reoperation due to complications of the index TEER procedure.\n* Recent ( \\\u003C 12 month) intracranial or intracerebral hemorrhage.\n* Recent ( \\\u003C 12 month) gastrointestinal ulcers or hemorrhage.\n* Hepatic disease with coagulopathy.(eg, Child-Pugh class B or C cirrhosis).\n* Allergy, intolerance, or contraindication to research drugs.\n* Participation in another investigational drug or device study within 30 days.\n* Indication for long-term OAC.\n* Absolute indication for dual antiplatelet therapy; (eg, recent PCI).\n* Life expectancy \\\u003C 12 months.\n* Pregnancy or breastfeeding.",{"count":194,"type":21},1032,[136],"Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients undergone TEER procedure. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients without an indication for OAC.",[198],"Mitral Regurgitation",[200,198,201,202,203,204,205,206,207,208,209,210,211,212],"Transcatheter Edge-to-Edge Repair (TEER)","Cardiovascular Diseases","Embolism and Thrombosis","Bleeding","Aspirin","Clopidogrel","Antithrombotic treatment","Platelet Aggregation Inhibitors","Antiplatelet Drug","Single Antiplatelet Therapy（SAPT）","Double Antiplatelet Therapy（DAPT）","Stroke","Myocardial Infarction","RECRUITING","2026-03-05",{"date":216,"type":31},"2026-03-09",{"date":218,"type":31},"2025-07-31",{"date":220,"type":21},"2029-09-30",{"name":37,"class":38},{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":78,"phases":232,"briefSummary":233,"conditions":234,"keywords":235,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":39},"100585369","phase-4-strategies-for-antithrombotic-treatment-following-transcatheter-edge-to-edge-repair-in-patients-with-an-indication-for-oral-anticoagulant-100585369","NCT06901466","STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-edge Repair in Patients With an Indication for Oral Anticoagulant: a Multicenter Randomized Controlled Trial","STAR-TEER Ⅰ","Inclusion Criteria:\n\n* Successful TEER procedure, defined as technical success per MVARC criteria.\n* Indication for long-term OAC.\n* Ability and willingness to comply with the trial protocol.\n* Provision of written informed consent.\n* Women of childbearing potential must use effective contraception from the time of consent until the final dose of antithrombotic therapy.\n* Antithrombotic strategy approved by the investigator.\n\nExclusion Criteria:\n\n* Severe renal impairment (creatinine clearance \\\u003C 15 mL\u002Fmin or requiring dialysis).\n* Ongoing postoperative bleeding (defined as overt bleeding with a ≥3.0 g\u002FdL drop in hemoglobin or requiring ≥3 units of blood transfusion), or vascular complications following the index TEER procedure.\n* Platelet count \\\u003C 50 × 10\\^9 \u002FL.\n* Need for reoperation due to complications of the index TEER procedure.\n* Recent ( \\\u003C 12 month) intracranial or intracerebral hemorrhage.\n* Recent ( \\\u003C 12 month) gastrointestinal ulcers or hemorrhage.\n* Hepatic disease with coagulopathy.(eg, Child-Pugh class B or C cirrhosis).\n* Allergy, intolerance, or contraindication to research drugs.\n* Participation in another investigational drug or device study within 30 days.\n* History of stroke or TIA within the past 6 weeks.\n* Absolute indication for anticoagulation in combination with antiplatelet therapy (eg, recent PCI).\n* Life expectancy \\\u003C 12 months.\n* Pregnancy or breastfeeding.",{"count":231,"type":21},880,[136],"Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups). Transcatheter edge-to-edge repair (TEER) is now a well-established strategy in high-risk patients with MR. Globally, over 250,000 patients have benefited from the TEER technique.Studies have shown that patients with severe mitral regurgitation exhibit a high prevalence of atrial fibrillation (AF), reaching up to 63%, which is an indication for long-term oral anticoagulation (OAC) therapy. However, no dedicated study has prospectively evaluated different antithrombotic strategies following TEER in patients with an indication for OAC. Current guidelines do not provide any recommendations for the antithrombotic management of TEER. Consequently, considerable treatment variation exists in clinical studies and practice. The investigators will conduct a multicenter, open-label randomized trial to compare different antithrombotic strategies following TEER in patients who have an indication for OAC.",[198],[200,198,201,202,203,204,236,206,237,207,211,212],"Rivaroxaban","Oral anticoagulation",{"date":216,"type":31},{"date":240,"type":31},"2025-06-13",{"date":242,"type":21},"2028-10-31",{"name":37,"class":38},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":78,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100628210","tavr-for-aortic-regurgitation-under-tte-guidance-100628210","NCT07458672","TAVR for Aortic Regurgitation Under TTE Guidance","Radiation- and Contrast-Free Transcatheter Aortic Valve Replacement for Aortic Regurgitation Under Transthoracic Echocardiography Guidance","Inclusion Criteria:\n\n* Age ≥18 years.\n* Severe native aortic regurgitation (AR) confirmed by echocardiography (per guideline-recommended multiparametric assessment).\n* Indication for intervention, defined as symptomatic severe AR (e.g., NYHA class II-IV) or asymptomatic severe AR with evidence of LV decompensation (e.g., reduced LVEF and\u002For LV dilation per guideline thresholds).\n* Deemed appropriate for transfemoral TAVR by a multidisciplinary Heart Team (e.g., elevated\u002Fprohibitive surgical risk or other clinical\u002Fanatomic factors favoring transcatheter therapy).\n\nExclusion Criteria:\n\n* Active infective endocarditis or ongoing systemic infection\u002Fsepsis.\n* Aortic pathology requiring open surgery, such as significant ascending aortic aneurysm\u002Froot disease above surgical thresholds, acute aortic syndrome, or other conditions where surgery is mandated.\n* Annulus\u002Flanding-zone dimensions outside device range",{"count":252,"type":21},30,[80],"Transcatheter aortic valve replacement (TAVR) is an established therapy for severe aortic valve disease, yet conventional workflows rely on fluoroscopy and iodinated contrast, exposing patients and operators to ionizing radiation and posing challenges for individuals with chronic kidney disease, contrast allergy, or other contraindications. In patients with native aortic regurgitation, the absence of annular\u002Fleaflet calcification and frequent annular dilation can further complicate device positioning and anchoring, increasing the procedural dependence on precise imaging guidance. Transthoracic echocardiography (TTE) provides real-time assessment of valve anatomy, coaxial alignment, depth control, and immediate hemodynamic results, and-when used as the primary imaging modality-offers a potential \"radiation- and contrast-free\" alternative for selected patients. However, clinical evidence for fully TTE-guided (echo-only) TAVR remains limited. Here, the investigators describe our procedural workflow and evaluate the feasibility and early outcomes of total TTE-guided TAVR for treating aortic regurgitation.",[256,257],"Aortic Regurgitation","Transcatheter Aortic Valve Replacement (TAVR)","2026-03-04",{"date":216,"type":31},{"date":261,"type":21},"2026-03-10",{"date":263,"type":21},"2027-12-31",{"name":37,"class":38},{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":78,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":280,"leadSponsor":282,"locationsCount":39},"100627839","tavr-for-aortic-regurgitation-under-tee-guidance-100627839","NCT07453849","TAVR for Aortic Regurgitation Under TEE Guidance","Radiation- and Contrast-Free TAVR for Aortic Regurgitation Under Transesophageal Echocardiography Guidance",{"count":252,"type":21},[80],"Under contemporary practice, transcatheter aortic valve replacement (TAVR) is typically performed with fluoroscopic visualization and repeated injections of iodinated contrast. While effective, this paradigm introduces cumulative radiation exposure to both patients and staff and can be problematic in individuals with renal dysfunction, prior contrast reactions, or other situations where contrast use is undesirable. Treating native aortic regurgitation (AR) adds another layer of complexity: limited valvular\u002Fannular calcification, enlarged annular dimensions, and dynamic root motion may reduce frictional \"purchase\" and make prosthesis stabilization more demanding, thereby heightening the need for continuous, high-fidelity intraprocedural imaging. Transesophageal echocardiography (TEE), with its close acoustic window to the aortic root, provides detailed real-time information on annular geometry, cusp coaptation, LVOT-aortic root alignment, guidewire trajectory, and implant depth, and it allows immediate confirmation of valve function and rapid recognition of adverse events (e.g., significant paravalvular regurgitation, maldeployment, pericardial effusion, or coronary compromise). Leveraging TEE as the dominant imaging modality therefore represents a pragmatic pathway toward a low-radiation and potentially contrast-sparing-or in selected cases, contrast-free-TAVR workflow. Nevertheless, evidence supporting an \"echo-only\" TEE-guided approach remains sparse, especially for native AR. In this study, we present a standardized TEE-guided procedural protocol and report feasibility and early clinical outcomes of TEE-only TAVR in patients with aortic regurgitation.",[256,275],"Transcatheter Aortic Valve Replacement","2026-03-02",{"date":278,"type":31},"2026-03-06",{"date":153,"type":21},{"date":281,"type":21},"2026-12-31",{"name":37,"class":38},{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":78,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":300,"locationsCount":39},"100595699","transaxillary-tavr-with-solely-echocardiography-guidance-100595699","NCT07035847","Transaxillary TAVR With Solely Echocardiography Guidance","Transaxillary Transcatheter Aortic Valve Replacement With Pure Echocardiography Guidance","Inclusion Criteria:\n\n1. symptomatic severe AS determined by echocardiography and Doppler that requiring aortic valve replacement, defined as: mean gradient ≥40 mmHg, peak aortic velocity ≥4 m\u002Fs, and aortic valve area (AVA) ≤1 cm2 (or an indexed AVA ≤0.6 cm2\u002Fm2)\n2. suitable for Transaxillary TAVR\n\nExclusion Criteria:\n\n1. required hybrid procedures or concomitant interventions on other cardiac malformations\n2. inoperable due to extremely high surgical risk or severe comorbidities\n3. untreated clinically significant (\\>70% obstruction) proximal vessel coronary vascular disease amenable to revascularization\n4. previously undergone aortic valve replacement.",{"count":122,"type":21},[80],"This study aims to evaluate the safety and feasibility of performing transaxillary transcatheter aortic valve replacement (TA TAVR) guided solely by echocardiography in patients with severe aortic stenosis (AS).",[52],"2026-02-26",{"date":296,"type":31},"2026-02-27",{"date":298,"type":31},"2024-10-01",{"date":281,"type":21},{"name":37,"class":38},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":39},"100618792","cmr-based-prognostic-study-in-patients-with-cardiac-implantable-electronic-devices-100618792","NCT07336225","CMR-Based Prognostic Study in Patients With Cardiac Implantable Electronic Devices","Prognostic Value of Cardiovascular Magnetic Resonance in Patients With Cardiac Implantable Electronic Devices","Inclusion Criteria:\n\n1. Adult patients (≥18 years old).\n2. Patients with guideline-based indications for cardiac implantable electronic device (CIED) therapy, including pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy.\n3. Patients who underwent cardiovascular magnetic resonance (CMR) imaging as part of routine clinical evaluation prior to CIED implantation or consideration of CIED therapy.\n\nExclusion Criteria:\n\n1. Patients younger than 18 years of age.\n2. Patients with non-diagnostic or poor-quality CMR images that preclude reliable image analysis.\n3. Patients with incomplete key clinical data or missing follow-up information for primary outcome assessment.\n4. Patients with prior heart transplantation or implantation of ventricular assist devices before CMR examination.\n5. Patients with congenital heart disease requiring surgical correction.",{"count":309,"type":21},1500,"Cardiac implantable electronic devices (CIEDs) are widely used to treat patients with heart failure, malignant arrhythmias, and other conditions. However, accurately identifying suitable candidates for CIED implantation remains a clinical challenge. Cardiovascular magnetic resonance imaging (CMR) provides a comprehensive assessment of cardiac structure, function, and tissue characteristics, facilitating evaluation of the myocardial substrate for arrhythmias. This study aims to evaluate the prognostic value of multiparametric CMR-derived imaging markers in CIED patients through preoperative CMR examinations. Imaging parameters of interest include structural-functional indices, myocardial strain, late gadolinium enhancement, entropy, and T1 and T2 mapping. Long-term clinical outcomes will be obtained from existing medical records and follow-up. The primary endpoint is sudden cardiac death (SCD) or SCD-equivalent events, defined as SCD, resuscitated cardiac arrest, sustained ventricular tachycardia or ventricular fibrillation, or appropriate ICD therapy. Secondary endpoints include all-cause mortality or heart failure rehospitalization. This study aims to elucidate the role of CMR in assessing CIED treatment indications and long-term risk stratification, thereby helping to optimize CIED implantation decisions.",[312],"Arrhythmias","2026-01-25",{"date":315,"type":31},"2026-01-27",{"date":317,"type":31},"2010-01-01",{"date":319,"type":21},"2040-12-31",{"name":37,"class":38},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":78,"phases":331,"briefSummary":332,"conditions":333,"keywords":338,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":39},"100606744","time-to-ambulation-after-proglide-closure-100606744","NCT07179536","Time to Ambulation After ProGlide Closure","Optimizing Time to Ambulation After ProGlide Closure of Femoral Access: A Randomized Controlled Trial","OPTIMA","Inclusion Criteria:\n\n* Scheduled for peripheral angiography or endovascular intervention via transfemoral access.\n* Femoral artery puncture site located at the common femoral artery.\n* Use of 6-8F vascular sheath.\n* Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure).\n* Preoperative ankle-brachial index (ABI) \\> 0.9 on both sides.\n* Conscious, cooperative, and with normal lower limb mobility.\n\nExclusion Criteria:\n\n* Undergoing carotid artery intervention.\n* Femoral artery diameter \\\u003C 5 mm, or effective lumen \\\u003C 5 mm due to plaque burden.\n* History of vascular complications at the puncture site.\n* Abnormal cardiopulmonary function.\n* Intraoperative platelet count \\\u003C 80 × 10⁹\u002FL, or use of thrombolytic agents.\n* Cognitive impairment, uncooperative, or limited lower limb mobility.","75 Years",{"count":108,"type":21},[80],"Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.",[334,335,336,337],"Femoral Access Site Closure","Ambulation","Vascular Access Complication","Vascular Access Site Management",[339,340,341,342],"Femoral access site closure","Vascular closure device","Time to ambulation","Vascular access complication","2026-01-21",{"date":345,"type":31},"2026-01-23",{"date":347,"type":31},"2025-10-01",{"date":349,"type":21},"2026-03-30",{"name":37,"class":38},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":358,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":361,"conditions":362,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":369,"locationsCount":39},"100619993","cardiac-magnetic-resonance-for-risk-stratification-in-non-dilated-left-ventricular-cardiomyopathy-100619993","NCT07351838","Cardiac Magnetic Resonance for Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy","Prognosis and Risk Stratification in Non-dilated Left Ventricular Cardiomyopathy : Cardiac MRI Insights for Better Outcomes","Inclusion Criteria:\n\n* age ≥ 16 years;\n* indexed left ventricular end-diastolic volume (LVEDVi) \\\u003C96 mL\u002Fm2 in females and \\\u003C105 mL\u002Fm2 in males at baseline cardiac magnetic resonance (CMR);\n* either left ventricular ejection fraction (LVEF) \\\u003C50% and\u002For non-ischemic left ventricular (LV) scar\u002Ffatty replacement at baseline cardiac magnetic resonance.\n\nExclusion Criteria:\n\n* lacked enhanced CMR images due to contraindications for receiving gadolinium contrast, such as severe renal disease;\n* ischemic heart disease, defined as stenosis of \\>50% in a major epicardial coronary artery underwent coronary computed tomography angiography or coronary angiography, ischemic late gadolinium enhancement (LGE) pattern on CMR indicating prior infarction, or prior coronary revascularization;\n* abnormal loading conditions, defined as moderate to severe valvular heart diseases, congenital heart diseases, uncontrolled hypertension;\n* systemic rheumatologic diseases or sarcoidosis;\n* diagnostic criteria for other cardiomyopathies according to the European Society of Cardiology (ESC) definitions.","16 Years",{"count":360,"type":21},1000,"Non-dilated left ventricular cardiomyopathy (NDLVC), a newly defined cardiomyopathy subtype characterized by non-ischemic myocardial abnormalities without left ventricular dilation, poses challenges in prognosis assessment and risk stratification. This is a retrospective observational study aiming to explore the prognostic value of cardiac magnetic resonance (CMR) findings and identify key risk factors for adverse cardiovascular outcomes in patients with NDLVC.\n\nWe will retrospectively enroll patients diagnosed with NDLVC who underwent CMR examination at the study institution during the predefined study period. CMR parameters, including left ventricular ejection fraction (LVEF), late gadolinium enhancement (LGE) patterns, myocardial strain, and the extent of myocardial fibrosis or fatty replacement, will be extracted and analyzed. The primary endpoint is a composite of major adverse cardiovascular events (MACE), including all-cause mortality, heart transplantation, or left ventricular assist device (LVAD) implantation.\n\nThe study intends to clarify the association between specific CMR features and long-term prognosis in NDLVC patients, thereby establishing a CMR-based risk stratification strategy to guide clinical decision-making and improve patient outcomes. Given the retrospective nature, data will be collected from electronic medical records and CMR databases, with ethical approval obtained prior to study initiation.",[363],"Non-ischemic Cardiomyopathy","2026-01-19",{"date":343,"type":31},{"date":317,"type":31},{"date":368,"type":21},"2030-12-30",{"name":37,"class":38},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":377,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":378,"targetDuration":379,"studyType":22,"phases":4,"briefSummary":380,"conditions":381,"keywords":389,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":398,"leadSponsor":399,"locationsCount":39},"100618805","precision-diagnosis-and-risk-stratification-of-rare-cardiomyopathies-based-on-novel-cardiac-magnetic-resonance-techniques-100618805","NCT07336394","Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques","Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Rare Cardiomyopathies - a Multicenter Study","Inclusion Criteria:\n\n* Patients who have received a cardiac magnetic resonance examination since 2010 and have a suspicion of rare cardiomyopathy.\n\nExclusion Criteria:\n\n* Severe arrhythmia;\n* Severe primary cardiac valvular disease;\n* Refuse to participate in the study.",true,{"count":360,"type":21},"10 Years","What is this study about? This research is focused on improving the care for people with rare heart muscle diseases, known as rare cardiomyopathies. These are uncommon conditions where the heart muscle becomes stiff, thick, or enlarged, making it harder for the heart to pump blood. Because they are rare, they can be difficult to diagnose and manage.\n\nThe investigators are testing new, advanced ways of using a heart scan called a Cardiac Magnetic Resonance (CMR). Participants can think of a CMR as a very powerful camera that takes detailed pictures of their heart without using radiation.\n\nWhat is the study trying to learn? Better Diagnosis: The investigators want to see if these new scanning techniques can help us identify these rare heart conditions more clearly and accurately. This means patients could get a correct diagnosis sooner.\n\nPersonalized Risk Assessment: The investigators want to see if the scan can help us understand the future risk for each patient better. For example, can it help predict which patients are more likely to have a heart rhythm problem or need specific treatments? This helps doctors create a care plan that is tailored just for participants.\n\nWhat does this mean for participants? If participants choose to take part, they will undergo a CMR scan that uses these new techniques. By participating, they will be helping us find better ways to diagnose and care for people with their condition in the future. The goal is to turn uncertainty into clearer, more personalized information for patients and families.",[382,383,384,385,386,387,388],"Danon Disease","Fabry Disease","Cardiac Amyloidosis","Noonan Syndrome","Cardiac Sarcoidosis","Glycogen Storage Disease","Idiopathic Cardiomyopathy",[390,391,392,393,394,395],"cardiovascular magnetic resonance imaging","early diagnosis","prognosis","rare cardiomyopathies","nuclear medicine imaging","echocardiography",{"date":343,"type":31},{"date":317,"type":31},{"date":368,"type":21},{"name":37,"class":38},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":377,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":39},"100620209","the-application-of-t1-mapping-in-real-world-100620209","NCT07354646","The Application of T1 Mapping in Real-World","The Landscape of T1 Mapping for Disease Profiling in a Real-World Cohort","Inclusion Criteria:\n\n1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.\n2. Specific disease categories include:\n\n   * Cardiomyopathies (HCM, DCM, RCM, ACM)\n   * Infiltrative disorders (cardiac amyloidosis, Fabry disease)\n   * Inflammatory conditions (acute\u002Fchronic myocarditis)\n   * Ischemic heart disease (acute\u002Fchronic MI)\n   * Valvular heart disease (aortic stenosis)\n   * Arrhythmic conditions (atrial fibrillation)\n   * Metabolic disorders (iron-overload)\n   * Neoplastic conditions (cardiac tumors)\n   * Congenital heart disease\n   * Post-transplant evaluation\n3. All diagnoses must be confirmed using established guideline-based criteria:\n\n   * Echocardiographic parameters meeting disease-specific cutoffs\n   * Cardiac MRI findings consistent with current consensus criteria\n   * Laboratory biomarkers supporting respective diagnoses\n   * Histopathological confirmation when clinically indicated\n\nExclusion Criteria:\n\n* Presence of multiple cardiomyopathy diseases or risk factors simultaneously\n* Contraindications to CMR examination\n* Poor image quality precluding accurate T1 mapping analysis\n* Incomplete clinical data for definitive diagnosis confirmation\n* Pregnancy or lactation\n* Inability to provide informed consent",{"count":408,"type":21},2000,"The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:\n\nWhat are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler \"native T1\" measurement (without contrast dye) instead of the more complex \"ECV\" measurement (which requires contrast dye) for diagnosis?\n\nPatients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping",[411,412,413,414,415],"Myocardial Infarction (MI)","Hypertrophic Cardiomyopathy (HCM)","Dilated Cardiomyopathy (DCM)","Arrhythmogenic Cardiomyopathy","Myocarditis","2026-01-12",{"date":343,"type":31},{"date":419,"type":31},"2020-03-01",{"date":421,"type":21},"2026-12-01",{"name":37,"class":38},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":430,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":39},"100619992","cmr-prognostic-markers-in-ischemic-heart-disease-100619992","NCT07351825","CMR Prognostic Markers in Ischemic Heart Disease","Prognostic Value of Multiparametric Cardiovascular Magnetic Resonance in Patients With Ischemic Heart Disease: A Multicenter Retrospective Cohort Study","Inclusion Criteria:\n\n1. Adults (≥18 years of age).\n2. Patients with ischemic heart disease, including prior or recent myocardial infarction, who underwent clinically indicated cardiac magnetic resonance (CMR) imaging.\n3. Availability of analyzable CMR images, including but not limited to cine imaging, late gadolinium enhancement (LGE), and parametric mapping sequences (T1 and\u002For T2 mapping), as applicable.\n4. Availability of baseline clinical data and longitudinal follow-up information.\n\nExclusion Criteria:\n\n1. Poor image quality or incomplete CMR data precluding quantitative analysis.\n2. Presence of other severe comorbid conditions expected to significantly affect survival or clinical outcomes.\n3. Missing key clinical outcome data during follow-up.",{"count":360,"type":21},"Ischemic heart disease (IHD) remains a leading cause of morbidity and mortality worldwide. Accurate risk stratification is essential for guiding clinical management and improving long-term outcomes in patients with ischemic myocardial injury.\n\nCardiovascular magnetic resonance (CMR) imaging provides comprehensive assessment of myocardial structure, function, and tissue characteristics, enabling detailed evaluation of ischemic injury and its consequences.\n\nThis multicenter, retrospective observational study aims to investigate the prognostic value of multiparametric CMR-derived imaging markers in patients with ischemic heart disease who underwent clinically indicated CMR examinations. Imaging parameters of interest include late gadolinium enhancement (LGE), infarct size, microvascular obstruction (MVO), left ventricular and left atrial strain, and native T1 and T2 mapping values.\n\nLong-term clinical outcomes will be obtained from existing medical records. The primary outcome is major adverse cardiovascular and cerebrovascular events (MACCE), and secondary outcome is cardiovascular death. This study seeks to clarify the role of CMR in long-term risk stratification of patients with ischemic heart disease.",[433,411],"Ischemic Heart Disease (IHD)",[435,436,437,438,439,440],"Ischemic heart disease","Cardiovascular magnetic resonance","Late gadolinium enhancement","Radiomics","Risk stratification","Prognosis","2026-01-11",{"date":443,"type":31},"2026-01-20",{"date":445,"type":31},"2009-01",{"date":447,"type":21},"2035-12",{"name":37,"class":38},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":377,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":456,"targetDuration":164,"studyType":22,"phases":4,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":39},"100618348","cardiovascular-surgery-early-prediction-system-for-aki-cards-aki-registry-100618348","NCT07330453","Cardiovascular Surgery Early Prediction System for AKI :CARDS-AKI Registry","Early Prediction and Clinical Outcomes of Cardiovascular Surgery-Associated Acute Kidney Injury: A Prospective Multicenter Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years；\n* Scheduled to undergo elective cardiac surgery；\n* Able to complete baseline data collection and provide written informed consent.\n\nExclusion Criteria:\n\n* Preoperative serum creatinine \\> 353 μmol\u002FL, history of or currently receiving dialysis therapy.\n* History of kidney transplantation.\n* Presence of malignant tumors.",{"count":457,"type":21},5000,"This multicenter, prospective study prospectively enrolled patients undergoing cardiovascular surgery. Detailed perioperative clinical data and biospecimens were collected at multiple time points. The primary aim is to develop an early warning model for postoperative acute kidney injury (AKI) by integrating clinical data and biomarkers. Additionally, through long-term follow-up, the study seeks to characterize outcome trajectories and establish a prognostic model for AKI patients.\n\nThis study addresses four key questions: 1) Integration of clinical information and biomarkers to develop an early predictive model for cardiac surgery-associated acute kidney injury (CSA-AKI); 2) Identification of risk factors for CSA-AKI occurrence; 3) Determinants of prognosis in patients with CSA-AKI; and 4) Enhanced prediction of near- and long-term clinical event risks in this patient population.\n\nParticipants will receive standard perioperative management. The study protocol includes the following procedures:(1) Clinical Data Collection: Comprehensive perioperative clinical data will be systematically recorded. (2) Biospecimen Sampling: Serial blood and urine samples will be obtained at predefined time points throughout the perioperative period. (3) In-Hospital Monitoring: Clinical outcomes will be continuously monitored during the hospital stay. (3) Post-discharge Follow-up: Participants will be assessed at regular intervals after discharge to track the occurrence of major adverse events.\n\nThese findings provide a foundational basis for the development of a data-driven early-warning system. Such a system is designed to facilitate the prompt identification of high-risk patients and enable the initiation of personalized treatment strategies, thereby potentially improving clinical outcomes and optimizing resource allocation",[460],"Cardiovascular Surgery","2026-01-04",{"date":463,"type":31},"2026-01-09",{"date":465,"type":21},"2025-12-25",{"date":467,"type":21},"2029-07-31",{"name":37,"class":38},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":476,"maxAge":18,"enrollmentInfo":477,"targetDuration":4,"studyType":78,"phases":479,"briefSummary":480,"conditions":481,"keywords":484,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":495},"100618177","superselective-adrenal-arterial-embolization-versus-oral-spironolactone-for-treatment-of-idiopathic-hyperaldosteronism-100618177","NCT07328230","Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism","A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone","Inclusion Criteria:\n\n1. Aged from 15 to 60 with no limits in sex;\n2. Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines;\n3. Sub-typing diagnosis confirmed idiopathic hyperaldosteronism;\n4. Patients or their legal representatives have to sign written informed consent approved by the ethics committee.\n\nExclusion Criteria:\n\n1. Unilateral adrenal hyperplasia;\n2. Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) \\\u003C45 ml\u002Fmin\u002F1.73 m², and\u002For serum creatinine \\>176 μmol\u002FL；\n3. Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months;\n4. Severe contrast agent allergy;\n5. Women who are pregnant or planning to become pregnant;\n6. Patients with other serious organic diseases cannot tolerate SAAE treatment;\n7. Other forms of secondary hypertension.","15 Years",{"count":478,"type":21},172,[80],"Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.",[482,483],"Idiopathic Hyperaldosteronism","Hyperaldosteronism",[485,486,483,84,487],"Superselective adrenal arterial embolization","Spironolactone","Mineralocorticoid receptor antagonists(","2025-12-26",{"date":463,"type":31},{"date":491,"type":31},"2022-08-01",{"date":493,"type":21},"2025-12-31",{"name":37,"class":38},3,{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":377,"sex":17,"minAge":504,"maxAge":132,"enrollmentInfo":505,"targetDuration":4,"studyType":78,"phases":506,"briefSummary":508,"conditions":509,"keywords":512,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":521,"locationsCount":522},"100485210","early-phase-1-effect-of-gut-microbiome-intervention-on-aging-via-oral-fmt-100485210","NCT05598112","Effect of Gut Microbiome Intervention on Aging Via Oral FMT","Effect of Fecal Microbiota Transplantation on Aging and the Underlying Mechanism of Gut Microbiome Restoration: a Randomized Clinical Trial","STEP-aging","Inclusion Criteria:\n\n1. Age 70-85 years.\n2. Patients with informed consent after thorough explanation.\n\nExclusion Criteria:\n\n1. Participants of other clinical trials;\n2. Antibiotics or probiotics usage within last 4 weeks;\n3. Severe hepatic or renal diseases ((ALT \\>3 times the upper limit of normal value, or end stage renal disease on dialysis or eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2, or serum creatinine \\>2.5 mg\u002Fdl \\[\\>221 μmol\u002FL\\]);\n4. History of large atherosclerotic cerebral infarction or hemorrhagic stroke (not including lacunar infarction and transient ischemic attack \\[TIA\\]);\n5. Hospitalization for myocardial infarction within last 6 months; Coronary revascularization (PCI or CABG) within last 12 months; Planned for PCI or CABG in the next 6 months;\n6. NYHA class III-IV heart failure; Hospitalization for chronic heart failure exacerbation within last 6 months;\n7. Severe valvular diseases; Potential for surgery or percutaneous valve replacement within the study period;\n8. Dilated cardiomyopathy; Hypertrophic cardiomyopathy; Rheumatic heart disease; Congenital heart disease;\n9. History of dementia, Parkinson's disease, intracranial infection, intracranial tumor, schizophrenia, anxiety, depression;\n10. History of neurosurgical operation;\n11. History of gastrointestinal tumor, gastrointestinal surgery, inflammatory bowel disease; Hospitalization for peptic ulcer disease exacerbation within last 6 months or anticipated hospitalization for peptic ulcer disease the next 6 months;\n12. Hypertension with uncontrolled blood pressure ≥180\u002F110mmHg;\n13. Diabetes Mellitus with uncontrolled fasting glucose level ≥200mg\u002Fdl (11.1mmol\u002FL), or HbA1C\\>8%;\n14. Addicted to alcohol; Use of medication influencing cognitive function(i.e., antihistamine, antipsychotic);\n15. General anesthesia within last 3 months;\n16. Other severe diseases influencing the entry or survival of participants, such as malignant tumor or acquired immune deficiency syndrome, life expectancy \\\u003C1 year;\n17. Impaired verbal communication who are incapable of providing their own informed consent, or incapable of self-care;\n18. Special diet influencing microbiota (i.e. vegetarian);\n19. Other conditions inappropriate for recruitment according to the investigators.","70 Years",{"count":20,"type":21},[507],"EARLY_PHASE1","A severe public health issue facing global population is aging. Increasing preclinical and clinical data indicate the contribution of gut microbiome on aging and aging-related diseases such as cardiovascular disease, Alzheimer Disease, and diabetes. Interventions on microbiota are developed including prebiotics, probiotics, and fecal microbial transplantation (FMT). FMT via oral capsules also advances in recent with limited safety concerns compared with invasive routes. A hypothesis is thus raised that gut microbiome intervention via oral FMT can be a potential safe approach to encourage healthy aging, with multiple aspects evaluated for clinical phenotype of frailty, anthropometric measurement, cognitive function, cardiovascular aging, physical function, living activity, hippocampal volume, telomere length, cognitive biomarkers, inflammatory biomarkers, altered microbial composition and metabolites.",[510,511],"Aging","Frailty",[510,511,513,514,515],"Microbiome","Treatment","Fecal Microbiota Transplantation","2025-12-24",{"date":493,"type":31},{"date":519,"type":31},"2023-04-24",{"date":263,"type":21},{"name":37,"class":38},6,{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":78,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":546,"locationsCount":547},"100531751","a-comparison-of-biodegradable-and-metal-occluders-in-patients-with-pfo-and-migraine-100531751","NCT06203873","A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine","BioMetal","Inclusion Criteria:\n\n1. Age 18-65\n2. Diagnosed migraine by ICHD-3\n3. History of migraine longer than 1 year, and symptoms severely disturbing daily life.\n4. TCD\u002FTTE\u002FTEE diagnosed patent foramen ovale with right to left shunt\n5. Willing to participant and agree to follow-ups\n6. Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.\n\nExclusion Criteria:\n\n1. Migraine caused by other reason\n2. Had TIA\u002Fstroke history\n3. With contraindication or hypersensitive to anti-platelet or anticoagulation drugs.\n4. With contraindication to PFO occlusion","65 Years",{"count":532,"type":21},400,[80],"Migraine is one of the most common chronic neurological disorders, posing a significant global public health concern. Patent Foramen Ovale (PFO) is the most common congenital heart anomaly in adults. Mechanisms linking PFO to migraine include cortical spreading depression, vascular active substance theory, impaired cerebral autoregulation, and genetic susceptibility. Understanding these mechanisms holds promise for overcoming challenges in the prevention and treatment of migraines in PFO patients. At least 11 observational studies, comprising 1,632 subjects, described the efficacy of PFO closure in cryptogenic stroke. Of these, 34% had migraines, and percutaneous PFO closure reportedly reduced migraine days by 81% (with a reduction of over 50% in monthly migraine days). Prospective randomized controlled trials (PRIMA and PREMIUM trials) assessing the Amplatzer® PFO Occluder showed significant benefits in most secondary endpoints, with a pooled analysis indicating its safety and effectiveness compared to medical therapy.While traditional metal PFO closure studies suggest symptom relief, reports also mention potential new-onset or worsened migraines post-closure. Proposed mechanisms include platelet activation, microthrombus formation, nickel allergy, and septal deformation or stretching inducing the release of migraine-related vascular active substances. However, these theories are closely tied to the presence of permanent metal implants.\n\nAddressing these concerns, the MemoSorb® biodegradable PFO Occluder system, approved by the National Medical Products Administration (NMPA) in September 2023, offers an innovative solution. Developed collaboratively by the National Biomedical Materials Engineering Technology Research Center, Professor Wang Yunbing\\'s team, Professor Pan Xiangbin\\'s team from Fuwai Hospital, Chinese Academy of Medical Sciences, and HeartTech Medical, this groundbreaking technology represents a shift from metal to degradable materials. The occluder serves as a temporary bridge post-implantation, gradually degrading with endothelialization, facilitating comprehensive self-repair. This intervention concept theoretically avoids the lifelong complications associated with traditional metal occluders, effectively reducing postoperative symptoms like migraines and dizziness.\n\nTo assess and compare the treatment outcomes, especially in relieving migraines, a prospective, single-blind, randomized controlled study has been designed for patients with patent foramen ovale and migraine, comparing the novel biodegradable occluder with the metal occluder.",[536,537,538,539],"PFO - Patent Foramen Ovale","Migraine","Migraine Headache","Migraine Headache, With or Without Aura","2025-11-27",{"date":542,"type":31},"2025-12-04",{"date":544,"type":31},"2024-03-01",{"date":153,"type":21},{"name":37,"class":38},2,{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":554,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":556,"targetDuration":557,"studyType":22,"phases":4,"briefSummary":558,"conditions":559,"keywords":562,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":568,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":574},"100612338","china-adrenal-venous-sampling-investigation-100612338","NCT07252284","CHina Adrenal Venous saMPling InvestigatiON","China Adrenal Venous Sampling Investigation: A National Multicenter Study","CHAMPION","Inclusion Criteria:\n\n1. Patients with confirmed primary aldosteronism;\n2. Patients undergoing adrenal venous sampling for subtype classification of primary aldosteronism.\n\nExclusion Criteria:\n\n1. Severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months；\n2. An estimated glomerular filtration rate \\\u003C45 ml\u002Fmin\u002F1.73 m2, or serum creatinine \\>176 μmol\u002FL；\n3. Patients who refuse adrenalectomy;\n4. Suspected of having an adrenocortical carcinoma;\n5. Allergy to contrast agent;\n6. Pregnant, nursing, or planning to become pregnant",{"count":457,"type":21},"5 Years","Primary aldosteronism (PA) is a major cause of secondary hypertension, yet its optimal diagnosis and management remain challenging. This study comprehensively evaluates adrenal venous sampling (AVS), addressing key clinical, technical, and methodological issues, and aims to clarify the relationship between AVS-guided management and long-term clinical and biochemical outcomes to optimize patient care and prognosis.",[483,560,561],"Adrenal Venous Sampling","Adrenalectomy",[563,483,564,565,566],"Adrenal venous sampling","Antecubital approach","Femoral approach","Main adverse cardiovascular events","2025-11-19",{"date":569,"type":31},"2025-11-26",{"date":571,"type":31},"2025-05-01",{"date":64,"type":21},{"name":37,"class":38},76,{"id":576,"slug":577,"hasResults":12,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":78,"phases":585,"briefSummary":586,"conditions":587,"keywords":4,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":567,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":596,"locationsCount":597},"100596633","interventions-for-silent-brain-infarction-and-perioperative-neurocognitive-disorders-in-cardiovascular-surgery-100596633","NCT07048002","Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery","Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery (the INSPIRE Study)","INSPIRE","Inclusion criteria:\n\n* Male or female adult patients aged 60 years or older\n* Receiving elective cardiovascular surgery with cardiopulmonary bypass\n* Written Informed consent provided\n\nExclusion criteria:\n\n* Contraindication to MRI scanning\n* Not suitable for receiving interventions to achieve NeuroFirst target bundle\n* Unable to receive neuro-cognitive evaluation due to language, vision, or hearing impairments\n* Breastfeeding or pregnancy\n* Terminal illness with a life expectancy of less than 3 months\n* Mental or legal disability\n* current enrollment in other interventional study",{"count":584,"type":21},912,[80],"the purpose of the study is to investigate whether a combined anesthetic targets bundle, known as the NeuroFirst strategy, focused on neurological protection, can reduce the incidence of silent brain infarction (SBI) and perioperative neurocognitive disorders (PND) in patients undergoing cardiac surgery. Additionally, the trial will assess the safety of this strategy.\n\nThe NeuroFirst target bundle incorporates multiple parameters, including mean arterial pressure (MAP), bispectral index (BIS), regional cerebral oxygen saturation (rSO2), and arterial inflow temperature during cardiopulmonary bypass.\n\nThe primary question this study seeks to answer is: Does the NeuroFirst strategy reduce the incidence of SBI and PND in cardiac surgery?\n\nTo address this, researchers will compare the NeuroFirst strategy with routine institutional practices based on published guidelines. Participants will be randomly assigned to either the NeuroFirst group or the routine care group. All participants will undergo magnetic resonance imaging (MRI), be assessed using the Confusion Assessment Method (CAM) and the Montreal Cognitive Assessment (MoCA), and be followed for up to one year postoperatively.",[588,589,26,590],"Silent Brain Infarction","Neurocognitive Disorders","Neuroprotective",{"date":592,"type":31},"2025-11-24",{"date":594,"type":31},"2025-07-06",{"date":242,"type":21},{"name":37,"class":38},5,{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":17,"minAge":74,"maxAge":329,"enrollmentInfo":606,"targetDuration":4,"studyType":78,"phases":608,"briefSummary":609,"conditions":610,"keywords":612,"overallStatus":213,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":623,"locationsCount":39},"100509094","quantitative-superior-vena-cava-isolation-in-addition-to-pulmonary-vein-isolation-for-paroxysmal-atrial-fibrillation-100509094","NCT05908955","Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation","Efficacy and Safety of Quantitative Superior Vena Cava Isolation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation: the SCORE Randomized Controlled Trial","SCORE","Inclusion Criteria:\n\n* Symptomatic paroxysmal AF that are unresponsive to antiarrhythmic drugs (one or more than one).\n* Willing to undergo catheter ablation for AF.\n* Age: 40-75 years old.\n\nExclusion Criteria:\n\n* History of any type of catheter ablation for cardiac arrhythmias.\n* History of any type of thoracic surgery, including cardiac surgery.\n* History of malignant tumors.\n* History of permanent pacemaker implantation.\n* Peripherally inserted central catheter for long-term\n* Heart failure (left ventricular ejection fraction ≤40% or NYHA class III\\~IV).\n* Sinus node dysfunction\n* Allergy to contrast agents.\n* Pregnancy or lactation.\n* Age: \\\u003C40yrs or \\>75yrs.",{"count":607,"type":21},290,[80],"Pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) has limited success. The superior vena cava (SVC) has been identified as one of the most common non-pulmonary vein triggers for PAF. It is estimated that SVC isolation (SVCI) could improve the clinical results for patients with PAF. However, results from previous studies about SVCI remain controversial. It is possible that safety concerns for SVCI outweigh its benefits and lead to inadequate ablation. To address this issue, the introduction of a quantitative ablation index (AI) for SVCI may provide a solution.\n\nThe goal of this prospective, randomized controlled trial is to test the efficacy and safety of quantitative SVCI in addition to PVI in PAF. Participants with PAF will be randomly assigned to either PVI group or PVI+ quantitative SVCI group in a 1:1 ratio and will be followed up for 12 months. The main questions it aims to answer are:\n\n1. Evaluate the efficacy of PVI+SVCI guided by quantitative AI.\n2. Assess the safety of PVI+SVCI guided by quantitative AI.\n\nThe primary end point is treatment success at 3 months after the index ablation. The secondary end points include treatment success at 12 months, and safety outcomes.",[611],"Atrial Fibrillation",[613,614,615,616],"Radiofrequency ablation","Pulmonary vein","superior vena cava","clinical trial","2025-02-12",{"date":619,"type":31},"2025-02-14",{"date":621,"type":31},"2024-03-17",{"date":493,"type":21},{"name":37,"class":38},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":628,"acronym":4,"eligibilityCriteria":629,"healthyVolunteers":12,"sex":17,"minAge":131,"maxAge":530,"enrollmentInfo":630,"targetDuration":4,"studyType":78,"phases":632,"briefSummary":633,"conditions":634,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":4},"100571261","early-phase-1-the-efficacy-and-safety-of-remimazolam-besylate-for-cardiac-anesthesia-100571261","NCT06717945","The Efficacy and Safety of Remimazolam Besylate for Cardiac Anesthesia","Inclusion Criteria:\n\n1. Elective cardiac surgery via cardiopulmonary bypass;\n2. Aged 18-65 years;\n3. American Society of Anesthesiologists (ASA) grade I-III;\n4. Body mass index (BMI) 18-28 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. A history of sternotomy for heart disease;\n2. Angina or arrhythmia with severe dynamics flutters pre-operation;\n3. Respiratory, hepatic or renal dysfunction (oxygenation index\\\u003C300, alanine transaminase\\> 2 upper limits of normal value, creatinine \\> 200 μmol\u002FL);\n4. Diagnosed with advanced tumors;\n5. Psychiatric or mental disorders;\n6. Myasthenia gravis or seizures;\n7. Pregnant or lactating females;\n8. A history of benzodiazepines administration within 3 months before surgery;\n9. Known allergic to benzodiazepines, opioids, propofol and flumazenil;\n10. Involved in another interventional clinical trial.",{"count":631,"type":21},320,[507],"The evidence on the practice of remimazolam besylate during cardiac anesthesia is scarce. This study investigates the efficacy and safety of remimazolam besylate general induction and maintenance during cardiac surgery.",[635],"Anesthesia","2024-12-01",{"date":638,"type":31},"2024-12-05",{"date":640,"type":21},"2025-01",{"date":642,"type":21},"2025-06",{"name":37,"class":38},""]